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Abstract: 
Inflammatory bowel disease (IBD) that include Crohn´s Disease (CD) and Ulcerative colitis (UC) 
are types of digestive system disease that steel have not been properly identified as their original 
causes. Our goal was to evaluation of lower infection with H.pylori in patients suffer from IBD in 
compete with the normal population. 
Method: IN this case-control study 146 patients with IBD (32 with CD and 114 with UC) and 146 
volunteers donated blood as control group were tested for IgG and IgA antibody against H.pylori 
since Dec 2017 from May 2018 in Shiraz that were randomly selected  from IBD registry software 
in motahari clinic. Result: The presence of H.pyloriIgG  was confirmed in 10 (31.2%) of CD, 37 
(32.4%) of patients with ulcerative colitis and 105 (71.9%) of the control group that it was 
significant (P< 0.001).The presence of H.pylori IgA  was confirmed in 25%of CD, 31.6% of 
patients with UC and 40.4% of the control group that it was not significant. In order to relation 
between IBD treatment regimens and presence of H.pylori IgG, there was significant differences 
between patients who received immune-modulator and immune-suppressive drugs and whom were 
not used these drugs.(p< 0.001). Conclusion: Our results show that the prevalence of serum IgG 
antibody against H pylori was significantly lower in patients with IBD than in controls. The use of 
immune-modulator and immune-suppressive drugs may reduce the involvement of IBD patients 
with Helicobacter pylori infection.  
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Intestinal inflammation (IBD), which includes Crohn's disease (CD) and Ulcerative colitis(UC), is 
a chronic, recurrent and prolonged illness that has caused many problems for global health(1, 2). 
Over time, the disease may lead to dyspepsia, surgery, or digestive discomfort(3, 4).IBD seems to 
be the result of unknown interactions between environmental factors (eg, infections, drugs, 
smoking, food) and host genetic factors resulting from inappropriate or anomal immunological 
reactions to intestinal microorganisms. The current hypothesis due to the etiology of IBD is that 
gastrointestinal microbes or their bio-products, in association with a disruption in the 
gastrointestinal epithelium and ⁄ or environmental trigger, distribute a deregulated immune 
response leading to chronic inflammation in genetically susceptible one(5, 6).For example, Gerald 
et al. (7) showed that infection with Campylobacteria or Salmonella species predisposes patients 
to the spread of IBD. 
The Helicobacter species are colonized in the gastrointestinal tract due to its micro-aerophilic 
metabolism, spiral shape and amazing mobility(8). The digestive tract growth site is divided into 
two major groups. The first group grows in the stomach, such as Helicobacter Pylori, and the 
second group, such as enterohepatic Helicobacter, which grows in the biliary system of the liver 
and is associated with chronic intestinal and gastrointestinal diseases(9). Helicobacter pylori 
usually resides at the epithelium of the stomach, but it can also be found in the colon and stool 
samples of patients(10). This fact raised the possibility that they may well play a role in the 
development or perpetuation of IBD(11).The inflammatory response of the stomach mucus to 
Helicobacter pylori is likely to signal the combined effects of cellular immune responses that are 
caused by bacteria through persistent stimulation of the host immune system(12). Local immune 
response products may go to other places of the body, and in turn, it can relate Helicobacter pylori 
infection to the pathophysiology of various types of gastrointestinal disorders, including 
autoimmune disorders (13). 
However, it is interesting to note that Helicobacter Pylori plays a protective role in the development 
of autoimmune disorders(14), such as asthma (15) and type I diabetes (16). The main role of the 
protective effects of Helicobacter Pylori infection in the treatment of acute or chronic localized 
mocusal is that it may be due to systemic cytokine secretion, which in turn leads to negative 
regulation of systemic immune responses and autoimmune suppression. An increase in the binding 
of gastrointestinal bacteria to intestinal epithelial cells has been reported in IBD. Intestinal 
inflammation (IBD), an intolerance to host immune responses to cumulative bacteria, has created 
a major pathogenic mechanism. The immune response to lymphocyte (Th1) cells and the secretion 
of pre-inflammatory cytokines in IBD, particularly Crohn's disease (CD), is involved. Positive 
cellular signaling molecules, such as macrophage inflammatory protein 3a (MIP-3a), have also 
been confirmed in IBD(17). 
H.pylori infection is an infectious disease that occurs in deprived societies and, in fact, improves 
the health of the environment, reducing its prevalence. On the contrary, an increase in the 
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prevalence of IBD is seen in Western-style populations (18).Therefore, it is clear that there is an 
inverse relationship between the outbreak of IBD and Helicobacter pylori infection. The 
prevalence of IBD in the United States is enormous, while the rate of infection with Helicobacter 
pylori is low. While in the area where treatment with Helicobacter Pylori is widely used, the 
constant increase in IBD is seen as endemic(17). Although environmental changes may 
corroborate this inverse relationship, many epidemiological studies have shown a lower incidence 
of Helicobacter Pylori infection in IBD patients(19). 
On the other hand, the drugs used in the treatment of IBD are those that enhance the Helicobacter 
Pylori, or IBD-associated mucosal changes prevent colonization of Helicobacter Pylori in the 
stomach(20, 21). Protective role in Helicobacter pylori infection with the mechanism of possible 
changes in host immune response to escape the inflammatory response of lymphocyte cells 1 and 
17 (Th1, Th17) to increase the activity of lymphocyte T cells can prevent the progression of 
IBD(22, 23). Additionally, Helicobacter Pylori may stimulate the production of antibacterial 
proteins that fight against bacteria that are potently effective in treating IBD (24), or with which 
bacteria compete for growth in the upper gastrointestinal tract (25). 
Material and method  
146 patients with IBD (32 Crohn´s and 114 Ulcerative Colitis) that was selected in the registry of 
inflammatory bowel disease patients in Motahari Clinic affiliated to Shiraz University of Medical 
Sciences, Iran, and 146 volunteers donated blood from Shiraz Blood Transfusion Organization as 
the control group (healthy non-IBD) since Dec 2017 from May 2018 in Shiraz  were included in 
the case-control study. The group of patients with IBD was randomly selected using randomized 
software( STATA ver 14.0). Their disease was confirmed by clinical diagnosis of two 
gastrointestinal specialists, laboratory and colonoscopy results. Demographic and disease 
information were extracted from the IBD registry software. In order to select normal group, any 
kind of clinical and/or histo-pathological diagnosis of IBD were excluded. All patients signed the 
form upon complete knowledge and understanding of the study conditions. This study was 
approved by the ethics committee of Shiraz University of Medical Sciences in May 2017 (code: 
6024). 
then the blood collection was done. Subsequently, the samples were transferred to the 
gastrointestinal lab, and the sera were divided into two parts and were kept in the -20ºC freezer 
until beginning of the experiments. H.PyloriIgG and H.Pylori IgA assay were performed on sera 
with enzyme-linked immune-absorbent assay(ELISA) method(Monobind, UK).A total of 146 
control blood donors from the Blood Donor who were matched for age and sex with inflammatory 
bowel disease were selected and the above tests were performed on them. 
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The data are analyzed using SPSS19 software. To evaluate the normality, the Kolmogorov smirnov 
test is used. Also, t-test, χ2-tests are used to compare the qualitative and quantitative variables 
between the groups as needed. To investigate the effect of confounding variables, are used. 
Results: 
The groupe of IBD patients consisted of 73 women, 13  (17.8%) had CD, 60 (82.2%) of them were 
UC. There were also 73 men in which 19 (26%) of them had CD, 54 (74%) had UC disease. The 
age range of the participants was 21 to 68 years old. A total of 146 healthy volunteers blood donors 
were selected as control group(none IBD). The age and sex were similar to those in the patients.  
The presence of H.pylori IgG in 152 participants (52.0%) was confirmed in both case and control 
groups, and 10 (31.2%) of Crohn's patients, 37 (32.4%) of patients with ulcerative colitis and 105 
(71.9%) of the control group were positive in this regard(P< 0.001)(Table1). 
 








DISEASE  Count 35 0 0 35 
% within 
DISEASE 
100.0% 0.0% 0.0% 100.0% 
UC Count 0 37 77 114 
% within 
DISEASE 
0.0% 32.5% 67.5% 100.0% 
CD Count 0 10 22 32 
% within 
DISEASE 
0.0% 31.3% 68.8% 100.0% 
NORMA
L 
Count 0 105 41 146 
% within 
DISEASE 
0.0% 71.9% 28.1% 100.0% 
 
The presence of H.pylori IgA in 103 participants (35.3%) was confirmed in both case and control 
groups, and 8 (25%) of Crohn's patients, 36 (31.6%) of patients with ulcerative colitis and 59 
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Table2:H.Pylori IgA ELIZA results 
 
DISEASE 







Count 36 8 59 103 
% within 
H.pyloriIgA 
35.0% 7.8% 57.3% 100.0% 
% within Disease 31.6% 25.0% 40.4% 35.3% 
NEGAT
IVE 
Count 78 24 87 189 
% within 
H.pyloriIgA 
41.3% 12.7% 46.0% 100.0% 
% within Disease 68.4% 75.0% 59.6% 64.7% 
 
In order to relation between IBD treatment regimens and presence of H.pylori IgG as shown in 
below table, there was significant differences between H.pylori positive and negative groups. 
Although 2 cases(50.0%) who consume “Pentasa” were positive for H.pylori IgG that was not 
significant, but 13 cases(33.3%) who are undergone “Glucocorticoid” treatment with H.pylori IgG 
Positive results, 18 cases (30.5%) undergone “Immunosuppressive” treatment, any cases(0.0%) of 
whom consumes “Asacol Enema”, 17 patients(32.0%) who are undergone ‘Asacol Suppository”, 
and 4 cases who were undergone “Mesalasin” treatment were positive also in this regard (p 
<0.001). 
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 In this study the presence of H.pylori IgG  was confirmed in 10 (31.2%) of CD, 37 (32.4%) of 
patients with ulcerative colitis and 105 (71.9%) of the control group that indicated the prevalence 
of serum IgG antibody against  H.pylori  was significantly lower in patients with IBD than in age 
and sex matched controls that was similar to recent study in other countries.(25-28) 
In order to relation between IBD treatment regimens and presence of H.pylori IgG, there was 
significant differences between patients who received immune-modulator and immune-
suppressive drugs (Glucocorticoid, Asacol Enema, Asacol Suppository, Mesalasin) and whom 
were not used these drugs. Although Some researchers reported that this was not related to any 
drugs used for IBD(34) but Some studies have represented that the rate of H. pylori is lower in the 
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IBD patients prescribed Immunosuppressive drugs(25, 26, 29, 30). Also El-Omar et al(27) 
suggested that the low prevalence of H pylori antibodies in patients with IBD was a result of long 
term treatment with sulphasalazine. (34).. Immunosuppressive drugs probably blocked the 
adhesion of H. pylori to the gastric mucosa directly over  
 
receptors or indirectly by its anti-inflammatory effects(32, 33).. There was some limitation in this 
study due to heterogeneity among studies regarding the method of H. pylori diagnosis differences 
in study population, ethnicity and age across study, and the possibility of publication bias may 
limit the certainty of the above findings. As environmental hygiene and intestina microbiota may 
be strong confounders, further mechanistic studies in H. pylori infection for instance using mouse 
models are necessary to define the mechanism. 
Conclusion: 
In this study we confirm that the presence of H.pylori IgG, was significantly lowert in patients 
who received immune-modulator and immune-suppressive drugs than whom were not received 
these medication. More studies investigating the effect of H. pylori infection eradication on the 
risk of development of IBD and the natural history of IBD are needed. 
Conflict of interest: The authors have no conflicts of interest in this study. 
References: 
1. Baumgart DC, Bernstein CN, Abbas Z, Colombel JF, Day AS, D'Haens G, et al. IBD 
Around the world: comparing the epidemiology, diagnosis, and treatment: proceedings of the 
World Digestive Health Day 2010--Inflammatory Bowel Disease Task Force meeting. Inflamm 
Bowel Dis. 2011;17:639-44. doi: 10.1002/ibd.21409. PubMed PMID: 20725944. 
2. Ko Y, Butcher R, Leong RW. Epidemiological studies of migration and environmental risk 
factors in the inflammatory bowel diseases. World J Gastroenterol. 2014;20:1238-47. doi: 
10.3748/wjg.v20.i5.1238. PubMed PMID: 24574798; PubMed Central PMCID: 
PMCPMC3921506. 
3. Fengming Y, Jianbing W. Biomarkers of inflammatory bowel disease. Dis Markers. 
2014;2014:710915. doi: 10.1155/2014/710915. PubMed PMID: 24963213; PubMed Central 
PMCID: PMCPMC4055235. 
4.JVV Antúnez (2016). Hipótesis para un derecho alternativo desde la perspectiva 
latinoamericana. Opción 32 (13), 7-10. 
5. Giaffer MH, Holdsworth CD, Duerden BI. Virulence properties of Escherichia coli strains 
isolated from patients with inflammatory bowel disease. Gut. 1992;33:646-50. PubMed PMID: 
1612481; PubMed Central PMCID: PMCPMC1379295. 
Helicobacter pylori infection and inflammatory bowel disease: is there a link? 




6. Zhang YZ, Li YY. Inflammatory bowel disease: pathogenesis. World J Gastroenterol. 
2014;20:91-9. doi: 10.3748/wjg.v20.i1.91. PubMed PMID: 24415861; PubMed Central PMCID: 
PMCPMC3886036. 
7. Gradel KO, Nielsen HL, Schonheyder HC, Ejlertsen T, Kristensen B, Nielsen H. Increased 
short- and long-term risk of inflammatory bowel disease after salmonella or campylobacter 
gastroenteritis. Gastroenterology. 2009;137:495-501. doi: 10.1053/j.gastro.2009.04.001. PubMed 
PMID: 19361507. 
8. Sonnenberg A. Review article: historic changes of Helicobacter pylori-associated diseases. 
Aliment Pharmacol Ther. 2013;38:329-42. doi: 10.1111/apt.12380. PubMed PMID: 23786250. 
9. M Nurgaliyeva, A Auyezova, A Kosmuratova (2018). Revisiting the role of independence 
formation and organizing individual work of the student in the educational process of HEI. Opción, 
Año 33, No. 85 (2018): 290-307. 
10. Willison HJ. Gangliosides as targets for autoimmune injury to the nervous system. Journal 
of neurochemistry. 2007;103:143-9. 
11. Kaakoush NO, Holmes J, Octavia S, Man SM, Zhang L, Castano-Rodriguez N, et al. 
Detection of Helicobacteraceae in intestinal biopsies of children with Crohn's disease. 
Helicobacter. 2010;15:549-57. doi: 10.1111/j.1523-5378.2010.00792.x. PubMed PMID: 
21073612. 
12. Naito M, Frirdich E, Fields JA, Pryjma M, Li J, Cameron A, et al. Effects of sequential 
Campylobacter jejuni 81-176 lipooligosaccharide core truncations on biofilm formation, stress 
survival, and pathogenesis. Journal of bacteriology. 2010;192:2182-92. 
13. van Amsterdam K, van Vliet AH, Kusters JG, van der Ende A. Of microbe and man: 
determinants of Helicobacter pylori-related diseases. FEMS Microbiol Rev. 2006;30:131-56. doi: 
10.1111/j.1574-6976.2005.00006.x. PubMed PMID: 16438683. 
14. Magen E, Delgado JS. Helicobacter pylori and skin autoimmune diseases. World J 
Gastroenterol. 2014;20:1510-6. doi: 10.3748/wjg.v20.i6.1510. PubMed PMID: 24587626; 
PubMed Central PMCID: PMCPMC3925859. 
15. Reibman J, Marmor M, Filner J, Fernandez-Beros ME, Rogers L, Perez-Perez GI, et al. 
Asthma is inversely associated with Helicobacter pylori status in an urban population. PLoS One. 
2008;3:e4060. doi: 10.1371/journal.pone.0004060. PubMed PMID: 19112508; PubMed Central 
PMCID: PMCPMC2603593. 
16. Krause I, Anaya JM, Fraser A, Barzilai O, Ram M, Abad V, et al. Anti-infectious antibodies 
and autoimmune-associated autoantibodies in patients with type I diabetes mellitus and their close 
family members. Ann N Y Acad Sci. 2009;1173:633-9. doi: 10.1111/j.1749-6632.2009.04619.x. 
PubMed PMID: 19758209. 
17. Thia KT, Loftus EV, Jr., Sandborn WJ, Yang SK. An update on the epidemiology of 
inflammatory bowel disease in Asia. Am J Gastroenterol. 2008;103:3167-82. doi: 10.1111/j.1572-
0241.2008.02158.x. PubMed PMID: 19086963. 
Helicobacter pylori infection and inflammatory bowel disease: is there a link? 




18. Koloski NA, Bret L, Radford-Smith G. Hygiene hypothesis in inflammatory bowel disease: 
a critical review of the literature. World J Gastroenterol. 2008;14:165-73. PubMed PMID: 
18186549; PubMed Central PMCID: PMCPMC2675108. 
19. Roka K, Roubani A, Stefanaki K, Panayotou I, Roma E, Chouliaras G. The prevalence of 
Helicobacter pylori gastritis in newly diagnosed children with inflammatory bowel disease. 
Helicobacter. 2014;19:400-5. doi: 10.1111/hel.12141. PubMed PMID: 24827117. 
20. Caner S, Altinbas A, Yesil Y, Beyazit Y, Yilmaz B, Yuksel O. The relation between 
Helicobacter pylori and ulcerative colitis. Turk J Med Sci. 2014;44:820-3. PubMed PMID: 
25539552. 
21. Xiang Z, Chen YP, Ye YF, Ma KF, Chen SH, Zheng L, et al. Helicobacter pylori and 
Crohn's disease: a retrospective single-center study from China. World J Gastroenterol. 
2013;19:4576-81. doi: 10.3748/wjg.v19.i28.4576. PubMed PMID: 23901235; PubMed Central 
PMCID: PMCPMC3725384. 
22. Lundgren A, Stromberg E, Sjoling A, Lindholm C, Enarsson K, Edebo A, et al. Mucosal 
FOXP3-expressing CD4+ CD25high regulatory T cells in Helicobacter pylori-infected patients. 
Infect Immun. 2005;73:523-31. doi: 10.1128/iai.73.1.523-531.2005. PubMed PMID: 15618192; 
PubMed Central PMCID: PMCPMC538965. 
23. Rad R, Brenner L, Bauer S, Schwendy S, Layland L, da Costa CP, et al. CD25+/Foxp3+ T 
cells regulate gastric inflammation and Helicobacter pylori colonization in vivo. Gastroenterology. 
2006;131:525-37. doi: 10.1053/j.gastro.2006.05.001. PubMed PMID: 16890606. 
24. Wehkamp J, Fellermann K, Herrlinger KR, Bevins CL, Stange EF. Mechanisms of disease: 
defensins in gastrointestinal diseases. Nat Clin Pract Gastroenterol Hepatol. 2005;2:406-15. doi: 
10.1038/ncpgasthep0265. PubMed PMID: 16265431. 
25. el-Omar E, Penman I, Cruikshank G, Dover S, Banerjee S, Williams C, et al. Low 
prevalence of Helicobacter pylori in inflammatory bowel disease: association with sulphasalazine. 
Gut. 1994;35:1385-8. PubMed PMID: 7959192; PubMed Central PMCID: PMCPMC1375010. 
26. Pearce CB, Duncan HD, Timmis L, Green JR. Assessment of the prevalence of infection 
with Helicobacter pylori in patients with inflammatory bowel disease. Eur J Gastroenterol Hepatol. 
2000;12:439-43. PubMed PMID: 10783998. 
27. Piodi LP, Bardella M, Rocchia C, Cesana BM, Baldassarri A, Quatrini M. Possible 
protective effect of 5-aminosalicylic acid on Helicobacter pylori infection in patients with 
inflammatory bowel disease. J Clin Gastroenterol. 2003;36:22-5. PubMed PMID: 12488702. 
28. Wagtmans MJ, Witte AM, Taylor DR, Biemond I, Veenendaal RA, Verspaget HW, et al. 
Low seroprevalence of Helicobacter pylori antibodies in historical sera of patients with Crohn's 
disease. Scand J Gastroenterol. 1997;32:712-8. PubMed PMID: 9246713. 
29. Parente F, Molteni P, Bollani S, Maconi G, Vago L, Duca PG, et al. Prevalence of 
Helicobacter pylori infection and related upper gastrointestinal lesions in patients with 
inflammatory bowel diseases. A cross-sectional study with matching. Scand J Gastroenterol. 
1997;32:1140-6. PubMed PMID: 9399396. 
Helicobacter pylori infection and inflammatory bowel disease: is there a link? 




30. Murad HA. Does Helicobacter pylori eradication therapy trigger or protect against Crohn's 
disease? Acta Gastroenterol Belg. 2016;79:349-54. PubMed PMID: 27821031. 
31. Smolka AJ, Backert S. How Helicobacter pylori infection controls gastric acid secretion. J 
Gastroenterol. 2012;47:609-18. doi: 10.1007/s00535-012-0592-1. PubMed PMID: 22565637. 
32. Stenson WF, Mehta J, Spilberg I. Sulfasalazine inhibition of binding of N-formyl-
methionyl-leucyl-phenylalanine (FMLP) to its receptor on human neutrophils. Biochem 
Pharmacol. 1984;33:407-12. PubMed PMID: 6142713. 
33. Taha AS, Sturrock RD, Russell RI. Helicobacter pylori and peptic ulcers in rheumatoid 
arthritis patients receiving gold, sulfasalazine, and nonsteroidal anti-inflammatory drugs. Am J 
Gastroenterol. 1992;87:1732-5. PubMed PMID: 1360191. 
 
